-
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung CancerDaiichi Sankyo2023-09-15 16:11:35ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung
-
ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 TrialDaiichi Sankyo2023-09-14 09:55:03ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung
-
Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b TrialDaiichi Sankyo2023-09-14 09:48:35Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small
-
Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase 1b trialDaiichi Sankyo2023-06-05 14:38:53Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small
-
ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid TumorsDaiichi Sankyo2023-06-08 21:19:11ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing
-
Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with Data at ASCO and EHADaiichi Sankyo2023-06-05 14:44:25Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with
-
Daiichi Sankyo Europe's Statement Regarding Esperion Therapeutics' ComplaintDaiichi Sankyo2023-05-08 11:25:47Daiichi Sankyo Europe's Statement Regarding Esperion Therapeutics' Complaint
-
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast CancerDaiichi Sankyo2023-01-31 12:28:25ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast
-
ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung CancerDaiichi Sankyo2023-01-04 14:32:17ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small
-
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low Metastatic Breast CancerDaiichi Sankyo2022-12-19 14:32:49ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low Metastatic Breast Cancer
